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Abstract
Objectives In this study, we aimed to investigate the effects of long-term administration
of the cardioprotective drug mildronate on the concentrations of l-carnitine and
g-butyrobetaine in healthy volunteers.
Methods Mildronate was administered perorally, at a dosage of 500 mg, twice daily.
Plasma and urine samples were collected weekly. Daily meat consumption within an
average, non-vegetarian diet was monitored. l-Carnitine, g-butyrobetaine and mildronate
concentrations were measured using the UPLC/MS/MS method.
Key findings After 4 weeks, the average concentrations of l-carnitine in plasma signifi-
cantly decreased by 18%. The plasma concentrations of g-butyrobetaine increased about
two-fold, and this effect was statistically significant in both the male and female groups. In
urine samples, a significant increase in l-carnitine and g-butyrobetaine levels was observed,
which provides evidence for increased excretion of both substances during the mildronate
treatment. At the end of the treatment period, the plasma concentration of mildronate was
20 mm on average. There were no significant differences between the effects observed in
female and male volunteers. Meat consumption partially reduced the l-carnitine-lowering
effects induced by mildronate.
Conclusions Long-term administration of mildronate significantly lowers l-carnitine
plasma concentrations in non-vegetarian, healthy volunteers.
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Introduction
The cardioprotective and anti-ischemic drug mildronate [3-(2,2,2-trimethylhydrazinium)
propionate dihydrate] is an inhibitor of the biosynthesis of l-carnitine[1] and its reabsorption
in the kidneys.[2] In experimental rat models, the administration of mildronate induces a
decrease in l-carnitine content and an increase in the concentration of g-butyrobetaine
(GBB), a bioprecursor of l-carnitine, in plasma and various tissues.[3,4] Because l-carnitine
is an essential molecule for free fatty acid oxidation and other metabolism pathways,[5,6] its
physiological concentration in body tissues is highly regulated by networks of biosynthesis
and transport.[7,8] l-carnitine is absorbed from dietary products, particularly meat and dairy
items.[9] It is also biosynthesised from lysine and methionine, and its excretion is efficiently
maintained by renal reabsorption.[9,10]
The effects of long-term mildronate administration on l-carnitine concentrations have
not been investigated in human subjects, even though the pharmacological effects of mil-
dronate are expected to occur via its regulatory effects on l-carnitine concentration, with
subsequent changes in downstream pathways of energy metabolism.[11,12] It is known that
mildronate treatment also affects the mitochondrial transport of l-carnitine and acylcar-
nitine.[13,14] Analytical procedures for the measurement of carnitine and its derivatives in
biological samples have been widely studied.[15–17] However, only scarce information is
available on the methods for simultaneous determination of l-carnitine and GBB.[15,18–20]
The pharmacokinetic investigations of mildronate in human subjects have been published
recently,[21,22] but simultaneous assessment of l-carnitine, GBB and mildronate in human
subjects has not been conducted before.
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This study was performed to measure for the first time in
human subjects the l-carnitine concentration-lowering effect
of mildronate, which was administrated at a cardioprotective
dose of 500 mg, twice a day as suggested by manufacturer. We
therefore applied a modification of a previously described
UPLC/MS/MS procedure[23] that yields good separation of
l-carnitine, GBB and mildronate in one analytical run on
a HILIC-type column. The effects of long-term mildronate
administration were evaluated in 17 healthy volunteers. Each
subject received 500 mg of mildronate twice daily for 4
weeks. Meat consumption was monitored to investigate the




This study was carried out after approval by the Central
Medical Ethics Committee of Latvia (20-05-2010) and
informed consent was obtained from all subjects. The study
population consisted of 17 healthy volunteers, 9 female and 8
male. The criteria for volunteers to participate in the study
were as follows: good health as assessed by clinical examina-
tion, non-smoking, not pregnant and no history of drug or
alcohol abuse. Data collected at the study inception included
age, medical history, anthropometric indices, total cholesterol
levels, triglyceride levels, creatinine levels and alanine tran-
saminase (ALAT) activity as a measure of liver function.
Blood plasma biochemical markers were measured using
clinically accepted methods. Mildronate was administered
perorally, at a dosage of 500 mg, twice daily between meals.
The subjects came to the trial unit at 8:30 am after fasting.
Urine aliquots and plasma samples were stored at -20°C prior
to analysis.
Materials
l-Carnitine was purchased from Lonza Ltd (Switzerland).
GBB and 3-(2,2-dimethyl-2-prop-1-yl-hydrazinium) propi-
onate (internal standard) were prepared by in-house methods.
Mildronate was a gift from J.S.C. Grindeks (Latvia). Aceto-
nitrile, methanol, ammonium acetate, formic acid, picric acid
and sodium hydroxide (NaOH) were purchased from Sigma-
Aldrich Co. (USA). Creatinine was obtained from Acros
Organics (Belgium). Water was purified by reverse osmosis
followed by purification with a MilliQ system. All solvents
and chemical reagents used were of the analytical grade.
UPLC/MS/MS assay
The concentrations of l-carnitine, GBB and mildronate in
human plasma and urine samples were measured using the
UPLC/MS/MS method, as previously described,[23] but with
minor modifications. Sample preparation consisted of simple
protein precipitation with acetonitrile–methanol solution. As
an internal standard, we used 3-(2,2-dimethyl-2-prop-1-yl-
hydrazinium) propionate for all calculations. Urine samples
were diluted 20-fold with water before analysis. Briefly,
100 ml of an acetonitrile-methanol mixture (3 : 1, v/v) con-
taining internal standard was added to 25 ml of plasma or
diluted urine sample. Samples were centrifuged at 11 000g for
10 min to precipitate proteins. The cleared supernatants were
removed and injected into the UPLC system (Acquity, Waters
Corp., 120 Manchester, UK). Chromatographic separation
was carried out on a BEH HILIC (1.7 mm, 2.1 ¥ 100 mm)
column (Waters Corp., 120 Manchester, UK) at a flow rate
of 0.25 ml/min. The composition of the mobile phase
–acetonitrile, 10 mm aqueous ammonium acetate (pH 4) –
varied linearly from 75 to 55% of acetonitrile. l-Carnitine,
GBB and mildronate were quantified by monitoring the spe-
cific transitions for each compound on the Micromass Quattro
Micro instrument (Waters Corp., 120 Manchester, UK).
Applied analytical procedures provided fair separation of
all analytes of interest in one run. The representative UPLC/
MS/MS plots of MRM-channels corresponding to internal
standard, l-carnitine, mildronate and GBB are presented in
Figure 1.
Assay of creatinine in urine samples
Creatinine concentrations were determined according to the
Jaffe method,[24] with some modifications. Briefly, 135 ml of
a reaction mixture containing one part of 0.6% of picric
acid/water solution and five parts of 1 m NaOH (mixed just
before the measurement) was added to 15 ml of diluted urine
samples or standard creatinine solutions (0–0.2 mg/ml).
After a 10-min incubation at room temperature, absorption
was measured spectrophotometrically in a 96-well plate
using a mQuant™ Microplate Spectrophotometer (BioTek) at
492 nm.
Statistical analyses and calculations
Results are expressed as the mean  standard deviation (SD)
or standard error mean (SEM). Statistically significant differ-
ences in the mean values between genders were tested by
Student’s t-test, and paired t-tests were used to compare the
differences from baseline. The differences were considered
significant when P < 0.05. The data were analysed using
GraphPad Prism 3.0 statistical software (GraphPad Inc.,
USA). Total body l-carnitine content was calculated based on
published data.[25–27] The amount of l-carnitine excreted in the
urine was calculated as the area under the curve, after taking
into account the average creatinine excretion rate. l-carnitine
consumed in the diet was calculated from meat consump-
tion data provided in the diet diaries of each study subject.
Correlation analysis was performed using Pearson’s correla-
tion test.
Results
Characteristics of study subjects
A summary of subject demographics and plasma biochemical
parameters is shown in Table 1. As shown in the table, the
average age, weight and body-mass index of the male and
female volunteers did not differ significantly. After the
4-week administration of mildronate there were no significant
changes in serum ALAT activity, triglyceride levels or total
cholesterol concentrations. Average meat consumption did not
differ significantly between male and female subjects, but in
females a larger deviation in meat consumption was observed
(Table 1). Mildronate treatment caused a decrease in plasma
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Figure 1 Representative UPLC/MS/MS plots of MRM channels corresponding to internal standard, l-carnitine, mildronate and GBB (from top to
bottom).
Table 1 A summary of demographic and plasma biochemical parameters of volunteers
Male (n = 8) Female (n = 9)
Mean  SD Range Mean  SD Range
Age, years 37  14 22–58 37  9 25–56
Height, cm 182  7 174–192 170  7** 157–180
Weight, kg 83  13 65–99 71  13 48–87
BMI, kg/m2 25  3 20–28 24  3 19–28
Meat consumption, g/day 156  26 125–200 156  54 100–275
Baseline
ALAT, U/l 31  20 11–74 24  8 15–38
Creatinine, mmol/l 83  12 73–98 72  9 59–91
Total cholesterol, mmol/l 5.1  1.3 3.7–8.0 5.1  0.8 3.6–6.0
Triglycerides, mmol/l 1.4  0.6 0.5–2.5 1.0  0.4 0.4–1.6
4 weeks
ALAT, U/l 31  12 10–47 20  8 13–37
Creatinine, mmol/l 71  10 58–87 64  10* 53–86
Total cholesterol, mmol/l 5.1  1.1 4.1–7.1 5.2  1.0 3.1–6.3
Triglycerides, mmol/l 1.4  0.5 0.9–2.3 0.9  0.4** 0.45–1.7
Biochemical parameters were determined in blood plasma samples before and after 4 weeks of mildronate administration. Values are represented as
the average  SD of eight to nine subjects. *Significantly different from baseline (paired t-test, P < 0.05). **Significantly different between genders
(Student’s t-test, P < 0.05).
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creatinine concentrations in male and female samples by 15
and 11%, respectively, but the effect was statistically signifi-
cant only for female volunteers (Table 1).
Analysis of plasma samples
Even at baseline, the l-carnitine concentrations in female
subjects were about 10% lower than in male subjects
(Figure 2a). As shown in Figure 2, mildronate induced time-
dependent changes in l-carnitine and GBB concentrations
in both female and male plasma samples. However, after 3
weeks of treatment, the statistically significant 11% reduction
in l-carnitine was found only in male samples (Figure 2a).
Notably, after 1 week of treatment the concentration of
l-carnitine in female plasma was slightly increased. At the
end of the 4-week treatment, the plasma concentrations of
l-carnitine were 16 and 20% lower than at baseline in male
and female samples, respectively. On average, mildronate
treatment induced a significant decrease in l-carnitine con-
centration of 18%.
In addition, plasma GBB concentrations changed after mil-
dronate treatment. As shown in Figure 2b, after only 1 week
of treatment, plasma GBB concentrations increased 61 and
76% in male and female samples, respectively. At the end
of the study, the plasma GBB levels increased 2.2-fold on
average, and this effect was statistically significant in both
the male and female groups.
Mildronate concentration increased gradually, approach-
ing a plateau in the female group after 1 week of treatment
(Figure 2c). In males, the increase was observed until week 2,
but then the plasma concentration of mildronate decreased,
reaching an average concentration of 20 nmol/ml (Figure 2c).
The average decrease in plasma l-carnitine concentration in
study subjects consuming less than 2 g of meat per kg of body
weight daily was 6.8  1.2 nmol/ml. In subjects consuming
more than 2 g/kg daily, the average decrease in l-carnitine
concentration in blood plasma was 2.4  3.4 nmol/ml. As
shown in Figure 3, the decrease in blood plasma l-carnitine
concentration significantly correlated with meat consumption
per kg of body weight (R = -0.54; P = 0.03).
Analysis of urine samples
The concentrations of l-carnitine, GBB and mildronate in
the urine samples mirrored the effects measured in plasma
samples. As shown in Figure 4a, in both female and male
samples, the excretion and concentration of l-carnitine sig-
nificantly increased after 1 week of mildronate treatment.
After 3 weeks, it levelled off until the end of the study at
around 330 nmol/mg creatinine (Figure 4a). The concentra-
tion of GBB increased 45-fold on average after 1 week, and
stayed at a significantly high level for the remaining period
of the study (Figure 4b). The concentration of mildronate










































































Figure 2 Concentrations in human plasma of (a) l-carnitine, (b) GBB
and (c) mildronate. l-carnitine, GBB and mildronate concentrations
were determined in blood plasma samples. Values are represented as the
average  SEM of eight to nine subjects. *Significantly different from
baseline (paired t-test, P < 0.05). #Significantly different between genders
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Figure 3 Correlation between the changes in blood plasma l-carnitine
concentration with meat consumption per kilogram of body weight.
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male and female samples (Figure 4c). After 3 to 4 weeks, a
slight decrease of 21% was observed in mildronate levels in
male samples. However, the difference was not significant
between male and female groups (Figure 4c).
Discussion
This is the first study to show that mildronate treatment
induces a significant decrease in l-carnitine levels and an
increase in GBB concentration in the blood plasma of healthy
non-vegetarian volunteers (Figure 2). However, the effect is
much lower compared to that observed in experimental rat and
mouse models, where 4-week treatment with a cardiopro-
tective dose of mildronate (100 mg/kg) at the same plasma
concentration (20 nmol/ml) induces up to a three-fold lower-
ing of l-carnitine levels and up to a six-fold increase in GBB
levels.[4,28] In experimental animals, a mildronate-induced
decrease in tissue l-carnitine content has been detected if the
plasma concentration of l-carnitine was several-fold lower
than in control animals.[4,23] Thus the recommended daily dose
of mildronate of 1 g/day is too low to achieve decreases in
l-carnitine concentration similar to those observed in animal
studies. A higher dose of mildronate might increase the effi-
cacy of mildronate treatment. Another finding of the present
study is the observation that mildronate treatment at a daily
dose of 1 g did not influence blood plasma triglycerides and
total cholesterol concentrations, as well as ALAT levels,
which confirms the safety of mildronate therapy.
In the volunteers of the present study, whole-body car-
nitine content was approximately 13.8 g. During the 28-day
mildronate treatment, the study subjects consumed 1.2 g of
l-carnitine in their diets (as calculated from the meat con-
sumption analysis), and they excreted by urine 3.5 g of
l-carnitine. Thus, the total overall body l-carnitine content
was reduced by 23%, and this effect is similar to that found
in blood plasma, where the l-carnitine concentration was
reduced by 18%. Urine sample analysis showed up to a three-
fold increase in l-carnitine excretion. It can therefore be
concluded that in non-vegetarian volunteers, long-term mildr-
onate treatment alters the plasma concentrations of l-carnitine
and GBB through the inhibition of renal re-uptake of these
molecules.
Mildronate is known to be an inhibitor of the biosynthesis
of l-carnitine[1] and its reabsorption in the kidney.[2] At the end
of the 4-week treatment, mildronate concentrations in blood
plasma reached 20 nmol/ml. According to animal studies, as a
result of active transport by OCTN2, the mildronate concen-
tration in tissues should be 30–50 times higher.[28,29] The Ki for
GBB hydroxylase enzyme inhibition by mildronate has been
determined to be 19 mm (enzyme prepared as described by
Tars et al.[30]), and the EC50 for OCTN2 inhibition by mild-
ronate was calculated to be 21 mm.[31] Thus, after long-term
treatment, the plasma concentration of mildronate reaches
a level that is able to induce changes in the homeostasis of
l-carnitine.
The pronounced l-carnitine concentration-lowering effect
of mildronate in experimental animals could also be a result of
low l-carnitine content in the animals’ diets, which could not
compensate for mildronate-induced excretion of l-carnitine.
The average non-vegetarian adult diet provides about 75% of
daily l-carnitine requirements.[32] In this study, our subjects
consumed about 40 mg (156 g meat) of l-carnitine daily, and
the urinary excretion of l-carnitine before mildronate treat-
ment was 30 mg/day. Thus, the relative l-carnitine absorption
from the diet in the subjects in the present study was 75%
and dietary l-carnitine provided all necessary l-carnitine.
l-carnitine concentrations in female blood plasma are signifi-
cantly lower than in males,[33] and l-carnitine-restricted diets
have little impact on total body carnitine because of efficient
renal reabsorption of carnitine.[27] The results of this study



























































































Figure 4 Concentrations in human urine of (a) l-carnitine, (b) GBB
and (c) mildronate. l-carnitine, GBB and mildronate concentrations
were determined in urine samples. Values are represented as the
average  SEM of eight to nine subjects. *Significantly different from
baseline (paired t-test, P < 0.05). #Significantly different between genders
(Student’s t-test, P < 0.05).
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plasma at baseline was 10% lower than those in male samples,
even if meat consumption is the same for the two groups
(Figure 2a). However, in study subjects consuming less meat,
the mildronate treatment decreased plasma l-carnitine con-
centrations up to three times more effectively. This result
indicates that meat consumption can provide amounts of
l-carnitine sufficiently high to mask the effects of mildronate.
In addition, the higher l-carnitine content in non-vegetarian
human diets compared to animal chow could explain the
weaker l-carnitine-lowering effect of mildronate observed in
the human volunteers compared to animal studies.
The use of the UPLC system instead of HPLC makes our
procedure particularly versatile for pharmacological studies
because of the very short (6 min) runtime. The monitoring of
mildronate-induced changes in l-carnitine and GBB concen-
trations could therefore serve as biochemical markers of
therapeutic efficiency.
Conclusion
Long-term administration of mildronate significantly lowered




The author(s) declare(s) that they have no conflicts of interest
to disclose.
Funding
This work was supported by the Latvian State Research Program
(grant number 2010.10–4/VPP-4), the European Social
Foundation (grant number 2009/0147/1DP/1.1.2.1.2/09/IPIA/
VIAA/009) and an European Regional Development Fund
grant (grant number 2DP/2.1.1.1.0/10/APIA/VIAA/063).
References
1. Simkhovich BZ et al. 3-(2,2,2-Trimethylhydrazinium)
propionate (THP)–a novel gamma-butyrobetaine hydroxylase
inhibitor with cardioprotective properties. Biochem Pharmacol
1988; 37: 195–202.
2. Kuwajima M et al. Pharmacokinetic analysis of the cardiopro-
tective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in
mice: inhibition of carnitine transport in kidney. J Pharmacol
Exp Ther 1999; 289: 93–102.
3. Hayashi Y et al. Beneficial effects of MET-88, a gamma-
butyrobetaine hydroxylase inhibitor in rats with heart failure
following myocardial infarction. Eur J Pharmacol 2000; 395:
217–224.
4. Liepinsh E et al. Mildronate, an inhibitor of carnitine biosynthe-
sis, induces an increase in gamma-butyrobetaine contents and
cardioprotection in isolated rat heart infarction. J Cardiovasc
Pharmacol 2006; 48: 314–319.
5. Bieber LL. Carnitine. Annu Rev Biochem 1988; 57: 261–283.
6. Foster DW. The role of the carnitine system in human metabo-
lism. Ann NY Acad Sci 2004; 1033: 1–16.
7. Chapela SP et al. Involvement of L-carnitine in cellular metabo-
lism: beyond Acyl-CoA transport. Mini Rev Med Chem 2009; 9:
1518–1526.
8. Indiveri C et al. The carnitine transporter network: interactions
with drugs. Curr Chem Biol 2010; 4: 108–123.
9. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of
L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci
2004; 1033: 30–41.
10. Rebouche CJ. Carnitine function and requirements during the
life cycle. FASEB J 1992; 6: 3379–3386.
11. Dambrova M et al. Mildronate: cardioprotective action through
carnitine-lowering effect. Trends Cardiovasc Med 2002; 12:
275–279.
12. Liepinsh E et al. Mildronate decreases carnitine availability and
up-regulates glucose uptake and related gene expression in the
mouse heart. Life Sci 2008; 83: 613–619.
13. Degrace P et al. Fatty acid oxidation and related gene expression
in heart depleted of carnitine by mildronate treatment in the rat.
Mol Cell Biochem 2004; 258: 171–182.
14. Oppedisano F et al. Interaction of mildronate with the mitochon-
drial carnitine/acylcarnitine transport protein. J Biochem Mol
Toxicol 2008; 22: 8–14.
15. Minkler PE et al. Strategy for the isolation, derivatization, chro-
matographic separation, and detection of carnitine and acylcar-
nitines. Anal Chem 2005; 77: 1448–1457.
16. Vernez L et al. Determination of carnitine and acylcarnitines in
urine by high-performance liquid chromatography-electrospray
ionization ion trap tandem mass spectrometry. J Chromatogr A
2003; 984: 203–213.
17. Vernez L et al. Determination of carnitine and acylcarnitines
in plasma by high-performance liquid chromatography/
electrospray ionization ion trap tandem mass spectrometry.
Rapid Commun Mass Spectrom 2004; 18: 1233–1238.
18. Davis AT et al. Dietary mildronate supplementation has no effect
on carnitine biosynthetic enzyme mRNA expression in rat. Nutr
Res 2007; 27: 225–229.
19. Hirche F et al. Determination of carnitine, its short chain acyl
esters and metabolic precursors trimethyllysine and gamma-
butyrobetaine by quasi-solid phase extraction and MS/MS detec-
tion. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:
2158–2162.
20. Vernez L et al. Effect of L-carnitine on the kinetics of carnitine,
acylcarnitines and butyrobetaine in long-term haemodialysis.
Nephrol Dial Transplant 2006; 21: 450–458.
21. Lv YF et al. Determination of mildronate in human plasma and
urine by liquid chromatography-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852:
35–39.
22. Peng Y et al. Determination of mildronate by LC-MS/MS and its
application to a pharmacokinetic study in healthy Chinese vol-
unteers. J Chromatogr B Analyt Technol Biomed Life Sci 2010;
878: 551–556.
23. Dambrova M et al. Effect of inhibiting carnitine biosynthesis on
male rat sexual performance. Physiol Behav 2008; 95: 341–347.
24. Jaffe M. Ueber die Niederschlag, welchen Pikrinsaure in nor-
malem Ham erzeugt und uber eine neue Reaction des Kreatinins.
Z physiol Chem 1886; 10: 391–400.
25. Calvani M et al. Carnitine replacement in end-stage renal disease
and hemodialysis. Ann NY Acad Sci 2004; 1033: 52–66.
26. Rebouche CJ, Engel AG. Kinetic compartmental analysis
of carnitine metabolism in the human carnitine deficiency syn-
dromes. Evidence for alterations in tissue carnitine transport.
J Clin Invest 1984; 73: 857–867.
27. Stanley CA. Carnitine deficiency disorders in children. Ann NY
Acad Sci 2004; 1033: 42–51.
28. Liepinsh E et al. Effects of long-term mildronate treatment on
cardiac and liver functions in rats. Basic Clin Pharmacol Toxicol
2009; 105: 387–394.







llibrary user on 06 July 2021
29. Grigat S et al. The carnitine transporter SLC22A5 is not a
general drug transporter, but it efficiently translocates mildr-
onate. Drug Metab Dispos 2009; 37: 330–337.
30. Tars K et al. Crystal structure of human gamma-butyrobetaine
hydroxylase. Biochem Biophys Res Commun 2010; 398: 634–
639.
31. Grube M et al. Uptake of cardiovascular drugs into the human
heart: expression, regulation, and function of the carnitine
transporter OCTN2 (SLC22A5). Circulation 2006; 113: 1114–
1122.
32. Longo N et al. Disorders of carnitine transport and the carnitine
cycle. Am J Med Genet C Semin Med Genet 2006; 142C: 77–
85.
33. Cederblad G. Plasma carnitine and body composition. Clin Chim
Acta 1976; 67: 207–212.







llibrary user on 06 July 2021
